Monoglyceride/lactate ester permeation enhancer for oxybutynin

Patent 5747065 Issued on May 5, 1998. Estimated Expiration Date:

March 15, 2016. Estimated Expiration Date is calculated based on simple USPTO term provisions. It does not account for terminal disclaimers, term adjustments, failure to pay maintenance fees, or other factors which might affect the term of a patent.

Abstract Claims Description Full Text

Patent References

3472931

3527864

3551554

3598122

3598123

3731683

3797494

3896238

3903256

Dermatological compositions
Patent #: 3952099
Issued on: 04/20/1976
Inventor: Smith

More ...

Inventors

Application

No. 617763 filed on 03/15/1996

US Classes:

424/448, Pressure sensitive adhesive means424/449, Transdermal or percutaneous514/946, PENETRANT OR ABSORBENT (ENHANCES PENETRATION INTO SUBJECT TREATED)514/947Topical application

Examiners

Primary: Phelan, D. Gabrielle

Attorney, Agent or Firm

Rafa; Michael J., Sabatine; Paul L., Stone; Steven F.

Foreign Patent References

0295411 EP 05/13/1988
0295411 EP 12/13/1988
0368339 EP 11/13/1989
0368409 EP. 05/13/1990
0368339 EP 05/13/1990
0431942 EP 12/13/1990
WO9220377 WO. 11/13/1992

International Class

A61F 013/02

Abstract

A composition of matter for application to a body surface or membrane to administer oxybutynin by permeation through the body surface or membrane, the composition comprising, in combination the oxybutynin to be administered, in a therapeutically effective amount; and a permeation enhancing mixture comprising a monoglyceride or a mixture of monoglycerides, and a lactic ester or a mixture of lactate esters, present in specific concentrations.

Other References

Tetrahedron Letters No. 20, pp. 1609-1612. Pergamon Press(1971). Hester, Jackson B., Duchamp, David J. Chidester, A Synthetic Approach to New 1,4-Benzodiazepine Dervatives
J. of Med. Chem., 1977, V. 20, pp. 1694, Walser, Armin and Zenchoff, Gladys, "Quinazolines and 1,4-Benzodiazepines. 81.¹ s-Triazolo4m3-a!1,4!benzodiazepines by Oxidative Cyclization of Hydrazones"
Current Ther. Res. Jun. 1976, V. 19, pp. 661-668, Nakajima; Take; Moriya; Saji; Yui; Nagawa, Pharmocological Studies on New Potent Central Depressants; 8-Chloro-6-Phenyl-4H-s-Triazolo
Naunyn-Schmiedeberg's Arch. Pharmacol. 301, pp. 157-161 (1978), Sethy, Vimala H. Sethy, "Effect of Hypnotic and Axiolytic Agents on Regional Concentration of Acetylcholine in Rat Brain"
Current Therapeutic Res., V. 19, No. 6, Jun. 1976, pp. 661-668, Fabre, Louis F., Jr., Pilot Open Label Study with Alprozolam (U31;889) in Outpatients with Neurotic Depression
J. Clin. Psychiatry 42:9, Sep. 1981 pp. 347-351, Cohn, Jay B., "Multicenter Double-Blind Efficacy and Safety Study Comparing Alprazolam, Diazepam and Placebo in Clincally Anxious Patients"
J. Clin. Psychiatry, 44,45 (1983) pp. 45-47, Abernethy, Greeblatt, Divol and Shader, "Pharmacokinetics of Alprazolam"
Pharmacotherapy, 2, (1982),pp. 243-254, Fawcett and Kravitz, "Alprozolam: Pharmacokinetics, Clincial Efficacy, and Mechanism of Action"
CRC Critical Review and Therapeutic Drug Carrier Systems, vol. 4, Issue 1 (1987) pp. 13-37 Knepp, Hadgraft, Guy, "Transdermal Drug Delivery: Problems and Possibilities"
J. of Pharmaceutical Sciences, V. 64, No. 6, Jun. 1975, pp. 901-924, Idson, "Percutaneous Absorption"
J. of Pharmacology & Experimental Therapeutics, V. 256, (1990) No. 2, pp. 562-567, Noronha-Blob and Kachur, Enantiomers Oxybutynin: In Vitro Pharmacological Characterization at M₁, M₂, M₃ Muscarinic etc
J. of Pharmacology & Experimental Therapeutics, V. 247, (1988) No. 3, pp. 867-872, Kachur et al., "R & S Enantiomers of Oxybutynin: Pharmacological Effects in Guinea Pig Bladder & Intestine